Biogen Valuation
| BIIB Stock | MXN 3,250 228.71 6.57% |
At this time, the firm appears to be overvalued. Biogen Inc shows a prevailing Real Value of 2898.0 per share. The current price of the firm is 3250.0. Our model approximates the value of Biogen Inc from analyzing the firm fundamentals such as Return On Equity of 0.2, current valuation of 861.61 B, and Profit Margin of 0.28 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Biogen's price fluctuation is very steady at this time. Calculation of the real value of Biogen Inc is based on 3 months time horizon. Increasing Biogen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biogen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biogen Stock. However, Biogen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3250.0 | Real 2898.0 | Hype 3250.0 | Naive 3251.93 |
The intrinsic value of Biogen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biogen's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Biogen Inc helps investors to forecast how Biogen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biogen more accurately as focusing exclusively on Biogen's fundamentals will not take into account other important factors: Biogen Total Value Analysis
Biogen Inc is currently anticipated to have takeover price of 861.61 B with market capitalization of 803.52 B, debt of 6.27 B, and cash on hands of 3.12 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Biogen fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
861.61 B | 803.52 B | 6.27 B | 3.12 B |
Biogen Investor Information
About 90.0% of the company shares are held by institutions such as insurance companies. The book value of Biogen was currently reported as 88.72. The company has Price/Earnings (P/E) ratio of 169.05. Biogen Inc recorded earning per share (EPS) of 370.65. The entity had not issued any dividends in recent years. Based on the analysis of Biogen's profitability, liquidity, and operating efficiency, Biogen Inc is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Biogen Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biogen has an asset utilization ratio of 45.99 percent. This suggests that the Company is making 0.46 for each dollar of assets. An increasing asset utilization means that Biogen Inc is more efficient with each dollar of assets it utilizes for everyday operations.Biogen Ownership Allocation
Biogen holds a total of 144 Million outstanding shares. The majority of Biogen Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biogen Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biogen. Please pay attention to any change in the institutional holdings of Biogen Inc as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Biogen Profitability Analysis
The company reported the revenue of 10.98 B. Net Income was 1.56 B with profit before overhead, payroll, taxes, and interest of 8.87 B.About Biogen Valuation
Our relative valuation model uses a comparative analysis of Biogen. We calculate exposure to Biogen's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biogen's related companies.Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. BIOGEN INC operates under Drug Manufacturers - Major classification in Mexico and is traded on Mexico Stock Exchange. It employs 7800 people.
8 Steps to conduct Biogen's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Biogen's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Biogen's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Biogen's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Biogen's revenue streams: Identify Biogen's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Biogen's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Biogen's growth potential: Evaluate Biogen's management, business model, and growth potential.
- Determine Biogen's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Biogen's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Biogen Stock Analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.